278 related articles for article (PubMed ID: 36840906)
1. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.
Shahvali S; Rahiman N; Jaafari MR; Arabi L
Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
3. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
[TBL] [Abstract][Full Text] [Related]
4. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Bughda R; Dimou P; D'Souza RR; Klampatsa A
Immunotargets Ther; 2021; 10():313-323. PubMed ID: 34386436
[TBL] [Abstract][Full Text] [Related]
7. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
8. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
9. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
10. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model.
Zhang FF; Qiao Y; Xie Y; Liu C; Wu H; Wu JX; Yu XH; Kong W; Zhang HH
Int Immunopharmacol; 2022 Nov; 112():109237. PubMed ID: 36152535
[TBL] [Abstract][Full Text] [Related]
11. Targeting fibroblast activation protein in cancer - Prospects and caveats.
Busek P; Mateu R; Zubal M; Kotackova L; Sedo A
Front Biosci (Landmark Ed); 2018 Jun; 23(10):1933-1968. PubMed ID: 29772538
[TBL] [Abstract][Full Text] [Related]
12. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.
Zhang Z; Tao J; Qiu J; Cao Z; Huang H; Xiao J; Zhang T
Cell Oncol (Dordr); 2024 Apr; 47(2):361-381. PubMed ID: 37726505
[TBL] [Abstract][Full Text] [Related]
13. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
[TBL] [Abstract][Full Text] [Related]
14. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.
Zhen Z; Tang W; Wang M; Zhou S; Wang H; Wu Z; Hao Z; Li Z; Liu L; Xie J
Nano Lett; 2017 Feb; 17(2):862-869. PubMed ID: 28027646
[TBL] [Abstract][Full Text] [Related]
15. Effects of the fibroblast activation protein on the invasion and migration of gastric cancer.
Wang RF; Zhang LH; Shan LH; Sun WG; Chai CC; Wu HM; Ibla JC; Wang LF; Liu JR
Exp Mol Pathol; 2013 Dec; 95(3):350-56. PubMed ID: 24422232
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
17. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
[TBL] [Abstract][Full Text] [Related]
18. Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Watanabe S; Noma K; Ohara T; Kashima H; Sato H; Kato T; Urano S; Katsube R; Hashimoto Y; Tazawa H; Kagawa S; Shirakawa Y; Kobayashi H; Fujiwara T
Cancer Biol Ther; 2019; 20(9):1234-1248. PubMed ID: 31185791
[TBL] [Abstract][Full Text] [Related]
19. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.
Cremasco V; Astarita JL; Grauel AL; Keerthivasan S; MacIsaac K; Woodruff MC; Wu M; Spel L; Santoro S; Amoozgar Z; Laszewski T; Migoni SC; Knoblich K; Fletcher AL; LaFleur M; Wucherpfennig KW; Pure E; Dranoff G; Carroll MC; Turley SJ
Cancer Immunol Res; 2018 Dec; 6(12):1472-1485. PubMed ID: 30266714
[TBL] [Abstract][Full Text] [Related]
20. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
